Abstract
The present study aimed to evaluate the peri-implantar bone healing in the presence of genistein treatment in ovariectomized rats. Thirty female rats with 4 months old were divided into 3 groups according to the experimental condition and the drug treatment: SHAM (rats submitted to the fictional surgery and gavage with 0.9% saline solution); OVX (rats submitted to bilateral ovariectomy and gavage with 0.9% saline solution); OVX GEN (rats submitted to bilateral ovariectomy and gavage with 1mg/day of genistein). 60 implants were installed, with two implants in each animal. The calcified group was subjected microcomputerized tomography and the parameters analysed was bone volume per tissue volume (BV/TV) and connective density (Cnn.Dn). The decalcified samples were evaluated through immunolabeling analysis, in order to detect the presence of RUNX2, Alkaline Phosphatase, Osteocalcin, Osteopontin and TRAP. All the quantitative data were submitted to the normality curve to determine the most adequate test. The significance level of p<0.05 was considered for all tests. The morphometric analysis of the OVX GEN group showed higher percentage of bone volume and lower connective density when compared with OVX. Immunohistochemical analysis favors expression. For the markers that positively label osteoblastic activity. This study shows that genistein therapy improves peri-implant bone healing in ovariectomized rats.
Highlights
Bone is a mineralized connective tissue that it is always remodeling through balance between the osteoblasts, osteocytes and osteoclasts cells
For connective density the values were in SHAM 0,00164 mm3, in OVX 0,00218 mm3 and in OVX GEN 0,00146 mm3
While for OVX GEN observed medium marking to RUNX2 makings of young osteoblastic lineage cells in the periimplant bone tissue
Summary
Bone is a mineralized connective tissue that it is always remodeling through balance between the osteoblasts, osteocytes and osteoclasts cells. Osteoporosis is a bone metabolic disorder mainly of postmenopausal women, with consequent reduction of estrogen levels It induces progressive bone loss and structural modifications of trabecular bone. There is a decrease of bone density, especially in the posterior region of maxillary bones This systemic interference decreases the primary stability (Merheb, et al 2016) and increases the marginal bone loss of implants (Giro, et al 2015). Both factors are directly crucial to the success of the implant treatment (Oliveira, et al 2017; Drage, et al 2007; Shapurian, et al 2006)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
